These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33652262)

  • 1. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality.
    Tarantino P; Mazzarella L; Marra A; Trapani D; Curigliano G
    Cancer Treat Rev; 2021 Mar; 94():102169. PubMed ID: 33652262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies.
    Russo A; Incorvaia L; Malapelle U; Del Re M; Capoluongo E; Vincenzi B; Chiari R; Cortesi L; Danesi R; Florena AM; Fontanini G; Gori S; Marchetti A; Normanno N; Pinto C; Sangiolo D; Silvestris N; Tagliaferri P; Tallini G; Cinieri S; Beretta GD
    Crit Rev Oncol Hematol; 2021 Sep; 165():103436. PubMed ID: 34371157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
    Seligson ND; Knepper TC; Ragg S; Walko CM
    Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histology-agnostic drug development - considering issues beyond the tissue.
    Pestana RC; Sen S; Hobbs BP; Hong DS
    Nat Rev Clin Oncol; 2020 Sep; 17(9):555-568. PubMed ID: 32528101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy.
    Vranic S; Gatalica Z
    Biomol Biomed; 2024 Jul; 24(4):673-675. PubMed ID: 38656302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers.
    Schroader B; Kong S; Anderson S; Williamson T; Sireci A; Shields K
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):929-938. PubMed ID: 31622558
    [No Abstract]   [Full Text] [Related]  

  • 8. Precision medicine in breast cancer: From clinical trials to clinical practice.
    Crimini E; Repetto M; Aftimos P; Botticelli A; Marchetti P; Curigliano G
    Cancer Treat Rev; 2021 Jul; 98():102223. PubMed ID: 34049187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
    Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
    Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histology agnosticism: Infra-molecularizing disease?
    Campbell J; Cambrosio A; Basik M
    Stud Hist Philos Sci; 2024 Apr; 104():14-22. PubMed ID: 38377771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue-Agnostic Drug Development: A New Path to Drug Approval.
    Thein KZ; Lemery SJ; Kummar S
    Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving landscape of tissue-agnostic therapies in precision oncology.
    Subbiah V; Gouda MA; Ryll B; Burris HA; Kurzrock R
    CA Cancer J Clin; 2024; 74(5):433-452. PubMed ID: 38814103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Does oncology change its paradigm? The challenge of agnostic approval of new therapies.].
    Martini N
    Recenti Prog Med; 2018 Jun; 109(6):317-318. PubMed ID: 29968857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of precision cancer medicine: Evolution of the treatment paradigm.
    Tsimberidou AM; Fountzilas E; Nikanjam M; Kurzrock R
    Cancer Treat Rev; 2020 Jun; 86():102019. PubMed ID: 32251926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor mutational burden as a tissue-agnostic biomarker for cancer immunotherapy.
    Sung WWY; Chow JCH; Cho WCS
    Expert Rev Clin Pharmacol; 2021 Feb; 14(2):141-143. PubMed ID: 33322961
    [No Abstract]   [Full Text] [Related]  

  • 17. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 18. The world of molecular cytopathology: Predictive testing and precision medicine: Highlights from the eighth International Molecular Cytopathology Meeting in Naples, Italy.
    Roy-Chowdhuri S; Rossi ED
    Cancer Cytopathol; 2020 Sep; 128(9):599-600. PubMed ID: 32885915
    [No Abstract]   [Full Text] [Related]  

  • 19. Precision Cancer Trials With Immunomodulatory Agents: Personalizing Histology Agnostic Approaches.
    Baretti M; Azad NS
    Cancer J; 2019; 25(4):287-295. PubMed ID: 31335393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database.
    Pestana RC; Serrano C
    Front Oncol; 2022; 12():1079909. PubMed ID: 36741731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.